iRECIST Overview

This time, we’d like to introduce you iRECIST. This criteria has been announced by the RECIST working group of the EORTC (European Agency for Research and Treatment of Cancer) in 2017.

Immunotherapy has been trends in oncological treatment. iRECIST describes how to measure and assess tumor size in immunotherapy clinical trials. We summarized the outline of this guideline here.
(May 11, 2020)

X/Twitter

This field is for validation purposes and should be left unchanged.

Your NameRequired

Email AddressRequired

*If you have set up domain rejection, please check your email receiving settings to allow emails from [@micron-kobe.com].

Company / OrganizationRequired

Department / Faculty NameRequired

Position

Phone Number

Purpose

Inquiry Details

Micron Updates

I would like to receive updates from Micron.

Notes on Contact Form

ConfirmationRequired

I agree to the above notes and confirm that I have reviewed the contents of this form.

Please feel free to contact us

We provide comprehensive, end‑to‑end clinical development support, with imaging at its core.

With more than 20 years of experience, our team of imaging specialists in Japan and around the world tackles the complex challenges of imaging evaluation in pharmaceutical and medical device development. We deliver optimal, project‑specific solutions for each client.

Downloads